Morfina Labesfal (Morphine Hydrochloride Trihydrate)

Morphine works by binding to mu‑opioid receptors in the brain, spinal cord and peripheral nervous system. This binding inhibits the release of pain‑transmitting neurotransmitters, reduces neuronal excitability, and raises the threshold for pain perception, resulting in effective analgesia while also producing sedation and respiratory effects.

The specific dose of Morfina Labesfal is determined by the prescribing clinician based on the patient’s age, weight, pain severity, prior opioid exposure, and clinical setting. Healthcare professionals calculate the appropriate amount and frequency to achieve adequate pain control while minimizing adverse effects.

Morphine is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used during pregnancy when the potential benefit justifies the potential risk. Morphine passes into breast milk; therefore, breastfeeding mothers should discuss alternatives with their healthcare provider.

To order Morfina Labesfal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Morfina Labesfal (morphine) is a benchmark opioid with well‑established efficacy for severe pain. Compared with synthetic opioids such as fentanyl, morphine has a longer history of use, a broader therapeutic window, and is less lipid‑soluble, which influences onset and duration. Choice of agent depends on pain type, required speed of onset, and patient‑specific factors.

Morfina Labesfal should be stored refrigerated at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Morfina Labesfal is supplied as a sterile injection solution and can be given intravenously, intramuscularly, or subcutaneously. The route, volume and rate of administration are determined by the prescribing clinician, who may use a syringe, infusion pump or other approved device according to standard aseptic techniques.

The most serious risks include severe respiratory depression, profound hypotension, and the potential for dependence or addiction. Patients should be closely monitored for signs of breathing difficulty, low blood pressure, and unusual sedation, especially when initiating therapy or when combined with other central nervous system depressants.

Morfina Labesfal is contraindicated in individuals with known hypersensitivity to morphine or any component of the formulation, in patients with severe respiratory depression, acute asthma attacks, or paralytic ileus. Caution is also advised for patients with uncontrolled head injury or increased intracranial pressure.